Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

Summary

This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Investigational" means that the drug is still being studied. It also means that the FDA has not yet approved afatinib for use in patients. In this research study the investigators are looking to see if taking afatinib after surgery works better when taken over a short period of time, compared to a long period of time.

Timeline

Start

2013-01

Primary completion

2020-11

Completion

2021-11

Drugs

Indications